Trial Profile
A retrospective study of Adalimumab and Infliximab combination with immune modulators on anti-TNF trough levels and antibodies in patients with inflammatory bowel disease
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Sep 2015
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary) ; Infliximab (Primary)
- Indications Inflammatory bowel diseases
- Focus Therapeutic Use
- 24 Sep 2015 New trial record